Cargando…

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab

Detalles Bibliográficos
Autores principales:	Pawlitzki, Marc, Teuber, Jan, Campe, Christin, Wagner, Markus, Schuart, Claudia, Paul, Friedemann, Bittner, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039210/ https://www.ncbi.nlm.nih.gov/pubmed/29998157 http://dx.doi.org/10.1212/NXI.0000000000000475

Ejemplares similares

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient
por: Massey, Thomas H., et al.
Publicado: (2017)

VZV in biopsy-positive and -negative giant cell arteritis: Analysis of 100+ temporal arteries
por: Gilden, Don, et al.
Publicado: (2016)

Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis
por: Frisch, Esther S., et al.
Publicado: (2023)

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports
por: Körtvélyessy, Peter, et al.
Publicado: (2017)

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
por: Hottinger, Andreas F., et al.
Publicado: (2018)

Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF
por: Kamourieh, Salwa, et al.
Publicado: (2017)

Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
por: Sood, Arjun B., et al.
Publicado: (2016)

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Acute liver injury in a Glatopa-treated patient with MS
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
por: Rempe, Torge, et al.
Publicado: (2020)

Microparticle-mediated VZV propagation and endothelial activation: Mechanism of VZV vasculopathy
por: Eleftheriou, Despina, et al.
Publicado: (2020)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Varicella zoster virus (VZV)-specific immunity and subclinical VZV reactivation in patients with autoimmune diseases
por: Lee, Kwang-Hoon, et al.
Publicado: (2021)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Acute retinal necrosis caused by co-infection with multiple viruses in a natalizumab-treated patient: a case report and brief review of literature
por: Cheraqpour, Kasra, et al.
Publicado: (2021)

IgA autoantibodies against native myelin basic protein in a patient with MS
por: Schumacher, Heike, et al.
Publicado: (2019)

Digital necrosis in an infant with severe spinal muscular atrophy
por: Carrasco, Diana, et al.
Publicado: (2019)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Enhancement of the Trigeminal Nerve by VZV Reactivation
por: Yaguchi, Hiroaki, et al.
Publicado: (2021)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3b9mjobcufmuqi7us1nap9klo6